Evidence map›Paper›PMID 41486257›Full record

ArticleJournal of ovarian research2026

Network pharmacology and molecular docking reveal the mechanism of Zishen Yutai Wan against polycystic ovary syndrome.

Zhu Ying, Zhu Hongqiu, Li Junjie, Wu Peijuan, Zhang Qian, Duan Mengxue, Li Yan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhu YingDepartment of Gynaecology, School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Zhu HongqiuDepartment of Gynaecology, School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China. zhuhongqiu@cdutcm.edu.cn.
Li JunjieDepartment of Gynaecology, School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Wu PeijuanDepartment of Gynaecology, School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Zhang QianDepartment of Gynaecology, School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Duan MengxueDepartment of Gynaecology, School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Li YanCDUTCM-KEELE Joint Health and Medical Sciences Institute, Chengdu, Sichuan, China.

Funding

Science and Technology Department of Sichuan, China 24NSFSC1648the Obstetrics and Gynecology Professional Committee of the Chinese Society of Integrated Traditional Chinese and Western Medicine FCK-ZSYTW-07
6 · The paper itself

Abstract

objectivesThe current treatments of polycystic ovarian syndrome (PCOS) have limited selectivity and effectiveness. Zishen Yutai Wan (ZSYTW) has shown therapeutic effects on patients with PCOS. This study aims to discover potential therapeutic targets and molecular mechanisms based on network pharmacology and molecular docking.

methodsA disease gene set related to PCOS was collected from three public databases, a ZSYTW target gene set was established using the Traditional Chinese Medicine Systems Pharmacology database and Traditional Chinese Medicine and Chemical Components Database, and an intersection of two gene sets to obtain intersecting genes. Protein-protein interaction (PPI) network were performed on intersecting genes. Molecular docking further confirmed the high affinity and stability between the active compounds of ZSYTW and core targets. Finally, PCOS model mice were used to verify the results.

resultsNetwork pharmacology showed that AKT1, TNF, IL6, TP53, and ESR1 were the key targets of ZSYTW against PCOS. Molecular docking demonstrated beta-sitosterol and stigmasterol exhibit strong binding affinities and binding stability with core targets, and p53 has the highest affinity with core components of ZSYTW. Mice experiment showed that compared with the control group, the expression of p53 protein and total apoptosis rate of ovarian granulosa cells in PCOS group were significantly increased (P < 0.001). And ZSYTW could decrease the increased expression of P53 protein and total apoptosis rate of granulosa cells (P < 0.001).

conclusionZSYTW could effectively improve PCOS by regulating p53 and apoptosis of ovarian granulosa cells.

Indexed as

Drugs, Chinese HerbalMolecular Docking SimulationNetwork PharmacologyPolycystic Ovary SyndromeAnimalsApoptosisDisease Models, AnimalFemaleGranulosa CellsHumansMedicine, Chinese TraditionalMiceProtein Interaction MapsDrugs, Chinese HerbalApoptosisMolecular dockingNetwork pharmacologyPolycystic ovary syndromeZishen yutai wan

Identifiers

PMID41486257
PMCPMC12882302

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.